< Go Back

Auxogyn Announces Oral Presentations on the Eeva™ Test at the Annual Meeting of the American Society for Reproductive Medicine
Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854
Cardiothoracic and Vascular Surgeons, in Collaboration with Heart Hospital of Austin, First in Texas to Implant Solo Smart™ Aortic Pericardial Heart Valve
Cypher Genomics Identifies and Verifies Genetic Cause of Rare Disease, Epileptic Encephalopathy
New Treatment Reported for a Potentially Fatal Lymphatic Complication in Children with Heart Disease
Global Alliance for Genomics and Health Members Meet to Advance Genomic Data Sharing
Milo Biotechnology's Follistatin Gene Therapy Increases Function in Becker Muscular Dystrophy Patients
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Autonomic Dysfunction in Parkinson's Disease With and Without Deep Brain Stimulation
Novel i-FACTOR™ Biologic Bone Graft Shown to Improve Clinical Outcomes in ALIF Procedures
Combining High Standards of Care with an Efficient Research Environment: Richmond Pharmacology Extends Capacity for Early Phase Studies in Patients
LabStyle Innovations to Demonstrate the Dario Smart Meter at the Upcoming Annual Canada Diabetes Association Conference
Eisai Announces FDA Acceptance of Supplemental New Drug Application for Antiepileptic Drug Perampanel as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
Boston Scientific Initiates Study Of Promus PREMIER™ Coronary Stent System In Underserved Patient Populations
Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy
Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs
BioNano Genomics Announces One Human : One Chip : One Day
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe
Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury
PneumRx Completes RENEW Pivotal Trial Enrollment Portuguese Spanish Spanish
CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society
Research Reveals Likelihood and Onset of Multiple Sclerosis Diagnosis Among Patients with Inflammatory Eye Disease
Lab-developed intestinal organoids form mature human tissue in mice
iPhones for Eye Health: Capturing Ocular Images in Difficult-to-Photograph Patients
Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition)
IMBRUVICA™ (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers
InnFocus Featured at the Ophthalmology Innovation Summit In Chicago
EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Nuvo Research® Sells PENNSAID® 2% U.S. Rights for US$45 Million to Horizon Pharma
CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting
Mediso Unveils the New MultiScan LFER 150 PET/CT Research Tool
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial
Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia
Personalized Cellular Therapy Achieves Complete Remission in 90 Percent of Acute Lymphoblastic Leukemia Patients Studied
New England Biolabs® Reveals Expanded NGS Sample Preparation Technology Pipeline at ASHG 2014
Pulmonary Fibrosis Foundation Applauds The Food And Drug Administration's (FDA) Prompt Decision To Approve Esbriet® (pirfenidone) And OFEV® (nintedanib) For The Treatment Of Idiopathic Pulmonary Fibrosis
Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide
Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, A Top Priority Addressed in the 2013 Presidential State of The Union, Announces Plan of "Creating 10,000 Regenerative Humans" Spanish Spanish Portuguese Spanish
S-equol Supplements Associated with Improvements in Measures of Reproductive Health in Postmenopausal Women
BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine
Novel Mutations Discovered In Cats Provide Insight Into Human Eye Diseases
Highland Therapeutics Announces Closing of US$25 Million Financing
Tetra Discovery Partners Announces Additional Financing and Formation of Scientific Advisory Board
Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics™
Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014
CytRx Appoints Steven A. Kriegsman as Chairman of the Board
FDA Approves Boehringer Ingelheim's OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
Novartis announces CTL019 data published in NEJM demonstrating efficacy in certain patients with acute lymphoblastic leukemia (ALL)

< Prev Next >
PR Newswire - United Business Media